Pharmaceuticals
SEC investigating Illumina over acquisition of cancer test developer Grail
A building on the campus at the world headquarters of Illumina is shown in San Diego, California, September 1, 2021. Mike Blake | Reuters The Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail, the DNA sequencing company said in a securities filing late Thursday. Last […]
Read More
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
Liselotte Sabroe | Afp | Getty Images Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company’s blockbuster weight loss portfolio. The deal is Novo Nordisk’s latest attempt to capitalize on the weight loss industry gold rush, which began […]
Read More
Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data
A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. Jim Vondruska | Reuters Novo Nordisk‘s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial – a landmark finding that could put more […]
Read More
Obesity drug Wegovy’s landmark trial result could ‘open up’ health insurance access, analyst says
A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023. Jim Vondruska | Reuters LONDON — Popular weight-loss drug Wegovy could be made available under more health insurance schemes, after the results of a late-stage trial pointed to the drug’s efficacy in […]
Read More
Novavax shares jump after Covid vaccine maker posts surprise quarterly profit
Medical syringes and Novavax logo displayed in the background are seen in this illustration photo taken in Krakow, Poland on December 2, 2021. Jakub Porzycki | NurPhoto | Getty Images Shares of Novavax jumped as much as 20% in premarket trading Tuesday after the Covid vaccine maker reported a surprise second-quarter profit. The results come […]
Read More
Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
Sopa Images | Lightrocket | Getty Images Eli Lilly on Tuesday raised its full-year guidance as second-quarter profit jumped 85% from the same period a year ago on strong sales from the pharmaceutical giant’s drug pipeline. The company now expects full-year revenue of between $33.4 billion to $33.9 billion, up from a previous forecast of […]
Read More
Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug
In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. Pavlo Gonchar | SOPA Images | Lightrocket | Getty Images Shares of Sage Therapeutics fell more than 50% on Monday after the Food and Drug Administration approved the biotech company’s oral drug zuranolone for […]
Read More
Here are the 5 price-target changes and 4 trades we made during this busy earnings week
In a jam-packed week of earnings, the Club executed multiple trades and elevated price targets for some of our biggest stocks. Many of these moves stemmed from what we saw in quarterly numbers and heard on conference calls. Here’s a day-by-day look at the portfolio action. Monday The week began with our decision to exit […]
Read More
Pfizer limits distribution of some drugs from North Carolina plant damaged by tornado
The roof of a Pfizer facility shows heavy damage after a tornado passed the area in Rocky Mount, North Carolina, July 19, 2023. ABC Affiliate WTVD | via Reuters Pfizer is limiting the distribution of some drugs manufactured at its plant in Rocky Mount, North Carolina after the facility was struck by a tornado last […]
Read More
Troubled health name bounces after strong quarter and guidance. Here’s our view on the stock
Troubled Club holding Bausch Health Companies (BHC) reported better-than-expected quarterly results before the bell Thursday. However, it’s not nearly enough to get this stock out of the penalty box. Sales in the second quarter rose 10% to $2.17 billion, exceeding expectations of $2.04 billion, according to estimates compiled by Refinitiv. (On an organic basis — […]
Read More